[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634572":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":26,"locations":32,"responsibleParty":52,"collaborators":11,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":11,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":11,"enrollmentInfo":63,"targetDuration":11,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":35,"whyStopped":11,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},{"fullName":5,"class":6},"Elpiscience Biopharma, Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Part1, Arm 1","EXPERIMENTAL",null,[13],"Drug: ES014",{"label":15,"type":10,"description":11,"interventionNames":16},"Part1, Arm 2",[13],[18,23],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","ES014","ES014 is administered via intravenous infusion, 700mg once every 14 days.",[9],{"type":19,"name":20,"description":24,"armGroupLabels":25,"otherNames":11},"ES014 is administered via intravenous infusion, 1400mg once every 14 days.",[15],[27],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"Jiayu Song","CONTACT","(+86) 21 50651310","ClinicalOperation@elpiscience.com",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Beijing Cancer Hospital","RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":42,"coordinates":43},"Point",[44,45],116.39723,39.9075,{"lat":45,"lon":44},[48],{"name":49,"role":29,"phone":50,"phoneExt":11,"email":51},"Lin Shen, Doctor","+86 1088196561","doctorshenlin@sina.cn",{"type":53,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100634572","phase-2-a-study-in-adults-with-desmoid-tumors-100634572",false,"NCT07541430","A Study in Adults With Desmoid Tumors","An Open-Label, Multicenter, Single-Arm Phase 2 Study of ES014 in Adult Subjects With Desmoid Tumors","Inclusion Criteria:\n\n* 1\\) Histologically confirmed desmoid tumor.\n* 2)Within 12 months prior to enrollment, meeting any of the following: Tumor target lesion growth ≥ 20% or appearance of new lesions;Desmoid tumor-related pain not adequately controlled by non-opioid medications.\n* 3)Meeting any of the following conditions: Subjects with recurrence or disease progression after at least one line of treatment (including surgery, radiotherapy, or systemic therapy, etc.); Treatment-naive subjects who are deemed suitable for the study drug by the investigator.\n* 4)Presence of at least one measurable lesion (according to RECIST v1.1).\n* 5)Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-2.\n* 6)Life expectancy of at least 12 weeks.\n* 7)Adequate hematologic, hepatic, renal and coagulation functions per protocol.\n* 8)Male and female subjects of childbearing potential must be willing to completely abstain or agree to use a highly effective method of contraception.\n\nExclusion Criteria:\n\n* 1)Any prior therapy targeting CD39, CD73, adenosine A2A receptor, or TGF-β.\n* 2)Receipt of any investigational agents or devices within 4 weeks prior to the first dose of study drug.\n* 3)Prior treatment with any of the following:\n\n  1. Anticancer therapy, including chemotherapy, tyrosine kinase inhibitors (TKIs), etc., within 28 days or 5 half-lives (whichever is shorter, but not less than 14 days) prior to the first dose of study drug.\n  2. For subjects who have received radiotherapy, a washout period of at least 2 weeks (limb radiation) or 4 weeks (chest, brain, or visceral organ radiation) is required before the start of study drug administration.\n  3. Traditional Chinese medicine (TCM) and proprietary Chinese medicines: if the package insert or investigator deems them to have clear anti-tumor effects, a 14-day washout is required. Other TCM and proprietary Chinese medicines do not require a washout.\n* 4)Prior allogeneic or autologous bone marrow transplantation or solid organ transplantation.\n* 5)Previous treatment-related toxicities unresolved to ≤ Grade 1, with the exception of alopecia (any grade), ≤ Grade 2 peripheral sensory neuropathy, and long-standing irreversible toxicities at the investigator's discretion.\n* 6)Major surgery within 4 weeks prior to the first dose of study treatment.\n* 7)Live vaccination therapies within 4 weeks prior to the first dose of study treatment.","ALL","18 Years",{"count":64,"type":65},50,"ESTIMATED","INTERVENTIONAL",[68],"PHASE2","This is an open-label, multicenter, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, tolerability, patient-reported outcomes (PROs), pharmacokinetics (PK), anti-drug antibody (ADA) and pharmacodynamics (PD) of ES014 in adult desmoid tumor patients.",[71],"Desmoid Tumor",[73,74,75],"CD39","TGF-β","CD39xTGF-β","2026-04-26",{"date":78,"type":79},"2026-04-30","ACTUAL",{"date":78,"type":65},{"date":82,"type":65},"2028-10",{"name":84,"class":6},"Elpiscience (Suzhou) Biopharma, Ltd.",1]